The Clarity AD clinical trial has shown relevant results in the study of Alzheimer’s disease, with data indicating a reduction in the rate of cognitive decline in patients.
Related Stories
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
28 de October de 2022
Dr Ernest Balaguer highlights the relevance of new therapeutic strategies in Alzheimer’s disease research, including…
3 de June de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
9 de January de 2020
We have reached the first position, in December 2019, in the international inclusion of patients…
12 de December de 2019
Grifols has reported to the press the positive result of the AMBAR trial in patients…
12 de November de 2019
On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial…
5 de November de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
31 de October de 2019
Neurology and Neuropsychology team specializes in the evaluation of biomarkers and the early diagnosis of…